Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01043029
Registration number
NCT01043029
Ethics application status
Date submitted
5/01/2010
Date registered
6/01/2010
Date last updated
2/11/2016
Titles & IDs
Public title
A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
Query!
Scientific title
Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®
Query!
Secondary ID [1]
0
0
2009-012270-12
Query!
Secondary ID [2]
0
0
BC22419
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus Type 2
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - aleglitazar
Treatment: Drugs - pioglitazone
Experimental: aleglitazar -
Active comparator: pioglitazone -
Treatment: Drugs: aleglitazar
Aleglitazar 150 mcg po daily for 52 weeks
Treatment: Drugs: pioglitazone
Pioglitazone 45 mg po daily for 52 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Renal function: estimated glomerular filtration rate
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Week 60
Query!
Secondary outcome [1]
0
0
Safety, Tolerability: Adverse events (AEs), laboratory parameters
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
AEs: Throughout study, laboratory assessments: Week 2, 4, 8, 12, 16, 20, 26, 39, 52, 56, 60
Query!
Secondary outcome [2]
0
0
Renal function: estimated glomerular filtration rate
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Week 52
Query!
Secondary outcome [3]
0
0
Effect on blood hemoglobin
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Week 52
Query!
Eligibility
Key inclusion criteria
* Adult patients >/= 18 years of age
* Diabetes mellitus, Type 2
* Moderately impaired kidney function
* Drug naive or up to 2 antihyperglycemic medications at stable dose for over 1 month at screening
* BMI 25-35
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Current or previous treatment with a thiazolidinedione
* Current or previous treatment with insulin
* Treatment with fibrates <3 months prior to screening
* History of renal disease other than diabetic nephropathy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/05/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
302
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC
Query!
Recruitment hospital [1]
0
0
- Camperdown
Query!
Recruitment hospital [2]
0
0
- St. Leonards
Query!
Recruitment hospital [3]
0
0
- Brisbane
Query!
Recruitment hospital [4]
0
0
- Elizabeth Vale
Query!
Recruitment hospital [5]
0
0
- Richmond
Query!
Recruitment hospital [6]
0
0
- Launceston
Query!
Recruitment hospital [7]
0
0
- Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2065 - St. Leonards
Query!
Recruitment postcode(s) [3]
0
0
4075 - Brisbane
Query!
Recruitment postcode(s) [4]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [5]
0
0
3121 - Richmond
Query!
Recruitment postcode(s) [6]
0
0
7001 - Launceston
Query!
Recruitment postcode(s) [7]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
Brazil
Query!
State/province [1]
0
0
CE
Query!
Country [2]
0
0
Brazil
Query!
State/province [2]
0
0
RS
Query!
Country [3]
0
0
Brazil
Query!
State/province [3]
0
0
SP
Query!
Country [4]
0
0
Colombia
Query!
State/province [4]
0
0
Barranquilla
Query!
Country [5]
0
0
Colombia
Query!
State/province [5]
0
0
Bogota
Query!
Country [6]
0
0
Colombia
Query!
State/province [6]
0
0
Bucaramanga
Query!
Country [7]
0
0
Colombia
Query!
State/province [7]
0
0
Medellin-Antioquia
Query!
Country [8]
0
0
El Salvador
Query!
State/province [8]
0
0
San Salvador
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Aschaffenburg
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Berlin
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Damme
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Dresden
Query!
Country [13]
0
0
Germany
Query!
State/province [13]
0
0
Essen
Query!
Country [14]
0
0
Germany
Query!
State/province [14]
0
0
Falkensee
Query!
Country [15]
0
0
Germany
Query!
State/province [15]
0
0
Mainz
Query!
Country [16]
0
0
Germany
Query!
State/province [16]
0
0
Münster
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Neuwied
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Reichenbach
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Rostock
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Sulzbach-Rosenberg
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Würzburg
Query!
Country [22]
0
0
Hong Kong
Query!
State/province [22]
0
0
Hong Kong
Query!
Country [23]
0
0
Hong Kong
Query!
State/province [23]
0
0
Tuen Mun
Query!
Country [24]
0
0
Hungary
Query!
State/province [24]
0
0
Baja
Query!
Country [25]
0
0
Hungary
Query!
State/province [25]
0
0
Budapest
Query!
Country [26]
0
0
Hungary
Query!
State/province [26]
0
0
Debrecen
Query!
Country [27]
0
0
Hungary
Query!
State/province [27]
0
0
Kecskemet
Query!
Country [28]
0
0
Hungary
Query!
State/province [28]
0
0
Miskolc
Query!
Country [29]
0
0
Hungary
Query!
State/province [29]
0
0
Satoraljaujhely
Query!
Country [30]
0
0
Hungary
Query!
State/province [30]
0
0
Szeged
Query!
Country [31]
0
0
Hungary
Query!
State/province [31]
0
0
Szekszard
Query!
Country [32]
0
0
Italy
Query!
State/province [32]
0
0
Liguria
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Lombardia
Query!
Country [34]
0
0
Mexico
Query!
State/province [34]
0
0
Aguascaliente
Query!
Country [35]
0
0
Mexico
Query!
State/province [35]
0
0
Chihuahua
Query!
Country [36]
0
0
Mexico
Query!
State/province [36]
0
0
Cuernavaca
Query!
Country [37]
0
0
Mexico
Query!
State/province [37]
0
0
Durango
Query!
Country [38]
0
0
Mexico
Query!
State/province [38]
0
0
Guadalajara
Query!
Country [39]
0
0
Mexico
Query!
State/province [39]
0
0
Pachuca
Query!
Country [40]
0
0
Peru
Query!
State/province [40]
0
0
Arequipa
Query!
Country [41]
0
0
Peru
Query!
State/province [41]
0
0
Lima
Query!
Country [42]
0
0
Romania
Query!
State/province [42]
0
0
Bucharest
Query!
Country [43]
0
0
Romania
Query!
State/province [43]
0
0
Cluj-napoca
Query!
Country [44]
0
0
Romania
Query!
State/province [44]
0
0
Iasi
Query!
Country [45]
0
0
Romania
Query!
State/province [45]
0
0
Ploiesti
Query!
Country [46]
0
0
Romania
Query!
State/province [46]
0
0
Sibiu
Query!
Country [47]
0
0
Romania
Query!
State/province [47]
0
0
Targu Mures
Query!
Country [48]
0
0
Russian Federation
Query!
State/province [48]
0
0
Chelyabinsk
Query!
Country [49]
0
0
Russian Federation
Query!
State/province [49]
0
0
Moscow
Query!
Country [50]
0
0
Russian Federation
Query!
State/province [50]
0
0
Saint-Petersburg
Query!
Country [51]
0
0
Russian Federation
Query!
State/province [51]
0
0
Saratov
Query!
Country [52]
0
0
Russian Federation
Query!
State/province [52]
0
0
St Petersburg
Query!
Country [53]
0
0
Russian Federation
Query!
State/province [53]
0
0
Yaroslavl
Query!
Country [54]
0
0
Slovakia
Query!
State/province [54]
0
0
Bratislava
Query!
Country [55]
0
0
Slovakia
Query!
State/province [55]
0
0
Dolny Kubin
Query!
Country [56]
0
0
Slovakia
Query!
State/province [56]
0
0
Levice
Query!
Country [57]
0
0
Slovakia
Query!
State/province [57]
0
0
Lucenec
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This multi-center, randomized, double-blind, active controlled, parallel-group study in type 2 diabetes patients with moderate renal impairment will evaluate the effect on renal function and the safety and tolerability of aleglitazar compared with pioglitazone. Patients will be randomized to receive either 150 mcg aleglitazar or 45 mg pioglitazone as daily oral doses. In addition, a diet and exercise plan will also be implemented during the anticipated time on study treatment of 52 weeks. The target sample size is 200-400 patients.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01043029
Query!
Trial related presentations / publications
Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Meyer-Reigner S, Mudie N, Wieczorek Kirk D, Malmberg K, Herz M. Effects of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study. BMC Nephrol. 2014 Nov 18;15:180. doi: 10.1186/1471-2369-15-180.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT01043029
Download to PDF